- Home
- FNLC vs VNDA Comparison
FNLC vs VNDA Comparison
Compare FNLC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FNLC | VNDA |
|---|---|---|
| Founded | 1864 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 402.2M | 361.4M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | FNLC | VNDA |
|---|---|---|
| Price | $35.30 | $5.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.90 |
| AVG Volume (30 Days) | 28.2K | ★ 804.4K |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.19% | N/A |
| EPS Growth | ★ 26.34 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | N/A | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $44.58 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $24.13 | $4.14 |
| 52 Week High | $36.30 | $9.91 |
Technical Indicators
Market Signals| Indicator | FNLC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 60.62 | 36.76 |
| Support Level | $32.73 | $4.94 |
| Resistance Level | $35.93 | $5.46 |
| Average True Range (ATR) | 1.25 | 0.21 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 73.56 | 27.73 |
Price Performance
Historical ComparisonAbout FNLC First Bancorp Inc (ME)
First Bancorp Inc is a Damariscotta-based bank holding company providing a range of retail and commercial banking services, including deposit accounts and consumer, commercial, and mortgage loans. The company provides investment management and private banking services through an operating division of the bank. Its revenues are generally derived from dividends paid to the company by the bank.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.